Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Xin Wang, Gaochao Guo, Hui Guan, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 239

Showing 1-25 of 239 citing articles:

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 827
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Christian Bailly, Xavier Thuru, Bruno Quesnel
NAR Cancer (2020) Vol. 2, Iss. 1
Open Access | Times Cited: 202
Frontiers in the treatment of glioblastoma: Past, present and emerging
Taskeen Iqbal Janjua, Prarthana Rewatkar, Aria Ahmed-Cox, et al.
Advanced Drug Delivery Reviews (2021) Vol. 171, pp. 108-138
Closed Access | Times Cited: 199
Functions and clinical significance of circular RNAs in glioma
Jikui Sun, Banban Li, Chang Shu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 156
STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma
Peng Zhang, Aida Rashidi, Junfei Zhao, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 114
Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients
Zihao Wang, Yaning Wang, Tianrui Yang, et al.
Briefings in Bioinformatics (2021) Vol. 22, Iss. 5
Open Access | Times Cited: 108
An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy
Shuhan Liu, Ji Liu, Haisong Li, et al.
Biomaterials (2022) Vol. 287, pp. 121645-121645
Closed Access | Times Cited: 78
Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets
Zhangfeng Zhong, Chi Teng Vong, Feiyu Chen, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1246-1279
Open Access | Times Cited: 75
Small molecule-based immunomodulators for cancer therapy
Yinrong Wu, Zichao Yang, Kui Cheng, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 12, pp. 4287-4308
Open Access | Times Cited: 70
Collagen architecture and signaling orchestrate cancer development
Hua Su, Michael Karin
Trends in cancer (2023) Vol. 9, Iss. 9, pp. 764-773
Closed Access | Times Cited: 45
IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment
Gilbert Aaron Lee, Justin Bo‐Kai Hsu, Yu-Wei Chang, et al.
Journal of Biomedical Science (2025) Vol. 32, Iss. 1
Open Access | Times Cited: 2
PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
Zhiyuan Zhu, Hongbo Zhang, Baodong Chen, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 121
Immunotherapy of brain metastases: breaking a “dogma”
Anna Maria Di Giacomo, Monica Valente, Alfonso Cerase, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 92
Advances in drug delivery technology for the treatment of glioblastoma multiforme
Gi Doo, Taegyu Kang, Seungmin Baik, et al.
Journal of Controlled Release (2020) Vol. 328, pp. 350-367
Closed Access | Times Cited: 76
Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy
Hongsheng Wang, Huangao Zhou, Jianing Xu, et al.
Cancer Letters (2020) Vol. 496, pp. 134-143
Open Access | Times Cited: 72
Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers
Yiyin Zhang, Qijiang Mao, Qiming Xia, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 64
Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
Mahmoud S. Alghamri, Brandon L. McClellan, Carson S. Hartlage, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 60
A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma
Hengrui Liu, Jieling Weng
Gene (2022) Vol. 822, pp. 146325-146325
Closed Access | Times Cited: 59
Emerging Role of PD-1 in the Central Nervous System and Brain Diseases
Junli Zhao, Alexus Roberts, Zilong Wang, et al.
Neuroscience Bulletin (2021) Vol. 37, Iss. 8, pp. 1188-1202
Open Access | Times Cited: 58
A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic Prediction
Hengrui Liu, Jieling Weng
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 58
In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma
Xiaoqi Wang, Lu Ye, Weichong He, et al.
Journal of Controlled Release (2022) Vol. 345, pp. 786-797
Closed Access | Times Cited: 53
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
Daniel Kreatsoulas, Chelsea Bolyard, Bill X. Wu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 50
Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma
Jiayang Cai, Yuanyuan Hu, Zhang Ye, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 45
Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products
Holya A. Lafta, Ali Hamid AbdulHussein, Saif A. J. Al-Shalah, et al.
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 12, pp. 1104-1122
Closed Access | Times Cited: 40
Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM
Bao Liu, Qifeng Ji, Ying Cheng, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top